Reading the ACOG 2026 Menopause Guideline: Twelve Changes and What They Mean
Start with the population, symptom and evidence, then discuss hormonal, nonhormonal and behavioural options together.

In this article
Compiled November 3, 2026 · For women aged 40+, families, and clinicians interested in evidence-based women’s health
In the consulting room, a 52-year-old woman shows her doctor a short video warning, “Never touch hormones during menopause,” and asks uncertainly, “Everyone online says this—would you still dare prescribe them?” This widely circulated fear traces back to an overextended interpretation of a 2002 study. On October 15, 2026, the American College of Obstetricians and Gynecologists (ACOG) published Clinical Practice Guideline No. 13 online, replacing Practice Bulletin No. 141 from 2014. Twelve years later, it seeks to bring hormone therapy out of a corner defined by fear and back to its evidence-based place. Here are the guideline’s twelve principal changes and their reasons.
I. Scope
I. Identify the guideline: the most comprehensive document on menopause symptom management
ACOG Clinical Practice Guideline No. 13, Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms, was published online in Obstetrics & Gynecology on October 15, 2026, replacing Practice Bulletin No. 141 of January 2014. It is ACOG’s most comprehensive evidence-based menopause symptom management guideline to date; even a specialist gynecology publication devoted its November menopause coverage to it.
It covers people assigned female at birth in perimenopause or postmenopause, including women, transgender men, and gender-diverse people, and symptoms related to natural or induced menopause from age 40 onward. Primary ovarian insufficiency before age 40 is outside its main scope. It therefore serves the broad population commonly described as “women aged 40+.”

Charyn Canyon
| Photograph:
Adam Harangozó
|
CC BY-SA 4.0
(cropped and resized)
Understanding the “grading system” comes first.
ACOG uses a modified GRADE framework. Each recommendation has two labels:
Strength of recommendation
(a strong recommendation, “ACOG recommends,” means benefits clearly outweigh harms and most patients should receive it; a conditional recommendation, “ACOG suggests,” means the balance depends on individual characteristics and preferences and requires shared decisions) +
Quality of evidence
(high/moderate/low/very low). There are also
3 good practice points
(ungraded statements on monitoring, discontinuation, and mood management). Each change below identifies its grade.
Although ACOG is a US organization, its guidance often shapes English-language evidence-based practice worldwide. This edition closely aligns with BMS–NICE 2026, IMS 2026, and ACP positions previously discussed here: MHT first-line, stratified nonhormonal options, individualized shared decisions, and attention to the timing window. Reading these documents together clarifies “global consensus” and helps clinicians in China interpret it for local practice.
II. Overview
II. From 2014 to 2026: twelve changes at a glance
| Number | Change | Reason in one sentence |
|---|---|---|
| ① | MHT becomes a strongly recommended first-line option | WHI reanalyses corrected blanket interpretations; efficacy is established |
| ② | A rigid “shortest duration” limit is removed | The timing-window concept supports ongoing reassessment |
| ③ | A clear initiation window: age 60 / 10 years | Thrombosis and stroke risks differ inside and outside the window |
| ④ | Dedicated recommendations address sleep and mood | The population burden is substantial; depression is not treated with MHT alone |
| ⑤ | NK receptor antagonists are added | A new mechanism independent of sex-hormone pathways |
| ⑥ | SSRIs/SNRIs receive a strong recommendation | Seven RCTs support options for VMS and depression |
| ⑦ | Gabapentin, clonidine, and oxybutynin are repositioned | Relative efficacy and safety require balancing |
| ⑧ | Nonpharmacological approaches are graded for the first time | Options when medication is declined/unsuitable; medication plus behavioral care |
| ⑨ | Botanicals and supplements are not recommended | Lack of evidence and oversight alongside excessive marketing |
| ⑩ | Health equity and earlier education receive emphasis | SWAN identifies a care gap: greater burden, lower treatment rates |
| ⑪ | Methods move to GRADE assessment | Greater transparency and practical usefulness |
| ⑫ | A dedicated GSM guideline is announced for 2027 | Narrower scope keeps different symptom groups separate |
III. The twelve changes explained
III. Twelve major changes and their reasons
Change one
MHT becomes a “strongly recommended” first-line treatment
The 2014 edition called for “the lowest dose for the shortest duration.” The new edition gives systemic hormone therapy for people without contraindications—estrogen plus progestogen with a uterus, estrogen alone without one—a strong recommendation, based on moderate-quality evidence, for vasomotor symptoms (VMS) and VMS-related sleep disturbance.
Reasons:
① WHI reanalyses corrected a blanket understanding of risk. Later evidence showed that MHT risks depend strongly on age, initiation timing, hormone type, and baseline health. The guideline specifically notes that nearly
67% of WHI participants were aged ≥60,
limiting extrapolation to younger women. ②
FDA labeling changes:
in 2025, the FDA removed boxed warnings about cardiovascular disease, breast cancer, and probable dementia from MHT labeling, providing a regulatory basis for revised guidance. ③
Established efficacy:
meta-analysis found estrogen, with or without progestogen, reduced VMS frequency (RR 0.43) and severity (RR 0.29) versus placebo/no treatment. In a network meta-analysis of 32 RCTs,
transdermal estradiol plus progestogen
ranked highest for reducing VMS frequency. ④ Coauthor Bruce Pier stated that misreading hormone risks had discouraged clinicians from prescribing and patients from using treatment; this guideline seeks to correct that.
Change two
A rigid “shortest duration” ceiling gives way to “individualized duration plus regular reassessment”
There is no fixed maximum course. Treatment rests on continuing risk assessment and shared decisions, with regular reassessment—effectiveness and tolerability three months after initiation, then annually. If persistent symptoms affect quality of life, continuation after age 60 remains possible.

Issyk-Kul Lake
| Photograph:
Bgag
|
CC0
(cropped and resized)
Reason:
New evidence supports the “timing hypothesis”: the benefit–risk balance should be
reassessed dynamically
as an individual’s risk profile changes, rather than restricted by a uniform limit. Returning the stopping decision to individualized assessment—one of three good practice points—can prevent unnecessary interruptions and symptom rebound caused by a mandatory stopping date.
Change three
A clear initiation window: before age 60 / within 10 years of menopause
For people with an indication who choose MHT, initiation is suggested before age 60 or within 10 years of natural menopause, with full discussion of cardiovascular, breast-cancer, and venous-thromboembolism risks.
Reason, based on risk-stratified data:
Initiation within the window is associated with lower coronary-heart-disease risk and similar stroke risk, but higher thrombosis risk. Initiation more than 10 years after menopause carries substantially greater thrombosis and stroke risks. The boundary is explicit:
MHT is not for antiaging or solely to “protect the heart and brain”;
its central purpose is treatment of clinically significant menopause symptoms.
Change four
Expanded scope: dedicated recommendations address sleep and mood/depressive symptoms for the first time
The 2014 bulletin concentrated on VMS. This edition specifically addresses VMS-related sleep disturbance and perimenopausal mood/depressive symptoms.
Reason:
The epidemiological burden is substantial: 16%–66% of US women report menopause-related sleep disturbance; over one-third of perimenopausal/postmenopausal women worldwide report depressive symptoms. Crucially, a good practice point states:
Evidence for MHT in menopause-related depression is insufficient to recommend for or against it.
People meeting major depressive disorder (MDD) criteria, or whose main problem is depression, should receive treatment according to depression guidelines.
MHT must not replace antidepressant treatment
.
Change five
A new nonhormonal class: NK receptor antagonists, fezolinetant and elinzanetant
For those unable or unwilling to use hormones, neurokinin receptor antagonists receive a strong recommendation as a new-mechanism option for VMS and VMS-related sleep disturbance:
• Fezolinetant (Veozah): NK-3 antagonist, 45 mg/day;
• Elinzanetant (Lynkuet): dual NK-1/3 antagonist, 120 mg/day; OASIS 1 showed both reduced VMS frequency and improved sleep at 12 weeks.

Streets in Bukhara’s old city
| Photograph:
Pixoos
|
CC BY-SA 4.0
(cropped and resized)
Reason:
The new mechanism blocks neurokinin B (NKB) signaling in the hypothalamic thermoregulatory center,
independently of sex-hormone pathways,
providing an option when hormones are contraindicated or declined. Different monitoring requirements matter: fezolinetant has a liver-injury boxed warning and requires testing at baseline, monthly for the first three months, and at months 6/9; elinzanetant requires baseline and three-month testing.
Change six
SSRIs/SNRIs receive a strong recommendation for nonhormonal treatment, addressing VMS and depression
For people not choosing hormones or with contraindications, SSRIs/SNRIs are strongly recommended for VMS and depression.
Reason:
A meta-analysis of 7 RCTs (N=1,676) found a moderate improvement in depression (Hedges g 0.44). Paroxetine 7.5 mg/day is the
only FDA-approved
antidepressant for VMS; others are off-label. An important interaction: fluoxetine/paroxetine are generally avoided with tamoxifen because they inhibit conversion to active endoxifen.
Change seven
Gabapentin, clonidine, and oxybutynin are repositioned
Gabapentin is a conditional option only when other nonhormonal medicines are ineffective/not tolerated; bedtime dosing can also support sleep. Clonidine is not recommended first-line. Oxybutynin is limited by anticholinergic effects, including cognitive concerns in older adults.
Reason:
Relative effectiveness–safety assessment moves medicines with weaker evidence or more prominent risks into reserve or avoidance categories, clarifying first-line choices.
Change eight
Nonpharmacological approaches receive grades for the first time: CBT, mindfulness, exercise, hypnosis, and acupuncture
Conditional recommendations support CBT for VMS/sleep/mood and mindfulness/exercise for sleep/mood. Hypnosis and acupuncture are additional conditional options, with low-quality evidence.
Reason:
These meet the needs of people unable/unwilling to use medication and encourage combined “medication plus behavioral” management. Some evidence remains limited; these approaches should complement medication rather than replace it.
Change nine
Explicitly “not recommended”: phytoestrogens, herbs, and supplements, including DHEA, testosterone, and progestogen alone
The guideline states that no evidence supports the safety/effectiveness of phytoestrogens such as soy isoflavones, herbs, and other dietary supplements and does not recommend them.

Bishkek Historical Museum
| Photograph:
Vilya Shoni
|
CC BY 4.0
(cropped and resized)
Reasons:
① No evidence-based assurance of safety, efficacy, or purity. ② No FDA oversight or purity/safety testing, alongside heavy marketing—a high-risk area the guideline specifically calls “misinformation.” ③ This matches this publication’s established distinction: phytoestrogens are SERM-like compounds binding weakly to estrogen receptors,
are nonhormonal, and cannot substitute for MHT
.
Change ten
Health equity and social determinants, with earlier patient education
The guideline separately considers racial, cultural, and socioeconomic influences on menopause experiences and access to care, emphasizing earlier and more comprehensive patient education.
Reason:
SWAN found Black women had greater symptom burden but lower treatment rates. The guideline seeks to close this care gap, reflecting the professional shift toward recognizing that menopause symptoms deserve treatment.
Change eleven
Upgraded methodology: a modified GRADE framework
Every recommendation carries strength (strong/conditional) and evidence-quality (high/moderate/low/very low) ratings. Three good practice points cover monitoring, discontinuation, and mood.
Reason:
Transparency and practical clarity help clinicians understand a grade and its underlying evidence, supporting shared decisions.
Change twelve
A companion announcement: a dedicated GSM guideline is planned for 2027
This guideline covers VMS, sleep, and mood. A guideline on genitourinary syndrome of menopause (GSM), including vaginal dryness/recurrent UTIs, is scheduled for 2027.

Pamir Plateau
| Photograph:
Hans Birger Nilsen
|
CC BY-SA 2.0
(cropped and resized)
Reason:
The scope centers on symptom groups with the strongest evidence; a separate GSM guideline avoids conflation.
One sentence to bring it together:
The twelve changes do not overturn a verdict. They regrade two decades of evidence overshadowed by fear using GRADE, restoring its place: hormone therapy returns to an appropriately timed first-line role, new nonhormonal options formally enter the framework, and botanicals are explicitly excluded.
In clinical practice: three reminders not to miss
①
Follow-up schedule:
After starting MHT,
assess at three months
for effectiveness and tolerability, then
reassess annually;
unexpected/persistent bleeding requires investigation for endometrial pathology.
②
NKRA liver monitoring:
fezolinetant: baseline, monthly for the first three months, months 6/9; elinzanetant: baseline and month 3. Do not omit liver-function testing.
③
Drug interactions:
avoid fluoxetine/paroxetine with tamoxifen; review concurrent medicines before prescribing.
IV. For readers in China
IV. Three practical implications for readers in China
- Do not let “hormones are terrifying” videos determine your decisions, but do not self-medicate. Strong recommendations require no contraindications, an appropriate window, and clinician assessment. Use guidance to support informed participation, not self-diagnosis.
- Match treatment to symptoms and circumstances rather than focusing only on hormones. For those with thrombosis/breast-cancer concerns, NKRAs and SSRIs/SNRIs are explicit first-line options; tamoxifen users should avoid paroxetine/fluoxetine. Bring “Which category applies to me?” to your appointment.
- Report hot flushes, poor sleep, and low mood together. The guideline treats them as a symptom cluster. Reporting only one leaves out their interaction and can prevent a complete plan.
This publication’s scope statement:
This article interprets a guideline and provides health education;
it is not diagnosis, treatment advice, or a recommendation for any product/brand.
Hormone therapy is consistently called MHT, often HRT in the United States. A treating clinician should develop your plan with you, based on history, risks, and preferences. Fezolinetant, elinzanetant, and bazedoxifene are prescription medicines; follow their prescribing information and your country’s guidelines for indications, contraindications, and monitoring.
V. Rapid reference review for clinicians
V. A rapid literature review for clinician readers
① ACOG. Clinical Practice Guideline No. 13: Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms. Obstet Gynecol. 2026 (online October 15, 2026).
The principal source for this interpretation. Modified GRADE; MHT strongly recommended with moderate-quality evidence for VMS/VMS-related sleep disturbance; strong recommendations for NKRAs and SSRIs/SNRIs; conditional gabapentin, clonidine not first choice; botanicals not recommended; initiation before 60/within 10 years of menopause; three good practice points (monitoring, stopping, mood).
② Women’s Health Initiative (WHI) Hormone Trials, 2002 (JAMA), and subsequent reanalyses
The source of widespread fear. Key correction: nearly two-thirds were ≥60, limiting extrapolation; risks vary by age, initiation timing, preparation, and baseline health.
③ Timing Hypothesis, Manson JE et al., 2013 and later work
Starting MHT before 60 or within 10 years of menopause gives a more favorable benefit–risk balance, supporting changes ②/③ on initiation timing and individualized duration.

Independence Monument Park, Ashgabat
| Photograph:
Hans Birger Nilsen
|
CC BY 2.0
(cropped and resized)
④ Key NKRA RCTs: phase 3 fezolinetant; elinzanetant OASIS 1/2/3, 2023–2024
They establish effectiveness of the central NKB mechanism for VMS. OASIS 1 found lower VMS frequency and better sleep at 12 weeks; differing liver-monitoring schedules appear in the medication notes.
⑤ SSRI/SNRI meta-analysis for VMS/depression (7 RCTs, N=1,676, Hedges g 0.44); FDA 2025 labeling changes; SWAN cohort
These support the depression evidence/tamoxifen-interaction warning in change ⑥. FDA removal of boxed warnings marks a regulatory turning point; SWAN supplies health-equity evidence for change ⑩.
Alternative headlines
Awei’s alternative headlines
- Twelve years later, ACOG brings hormone therapy back to first-line menopause care [number + authority + personification]
- Was “never use hormones during menopause” wrong? ACOG 2026 revisits the claim [counterintuitive + curiosity]
- The same hot flushes and sleeplessness: one woman is told to endure, another receives a strongly recommended prescription [contrasting difficulties + identification]
- ACOG 2026 in one table: twelve changes and what they mean for you [number + practical checklist]
- Soy isoflavones explicitly “not recommended”: this ACOG guideline separates evidence from misconception [counterintuitive + correction]
Sources
Sources and further reading
① ACOG Clinical Practice Guideline No. 13 (Obstet Gynecol, online October 15, 2026); ② official ACOG press release (October 2026); ③ Contemporary OB/GYN / Epocrates / Patient Care Online / Medical Daily summaries; ④ Chinese guides from Medlive, MedSci, and others (October 2026); ⑤ WHI 2002 (JAMA), Manson 2013 timing hypothesis, phase 3 NKRA RCTs (OASIS 1/2/3), SSRI/SNRI meta-analysis (7 RCTs, N=1,676), FDA 2025 labeling changes, SWAN, BMS–NICE 2026 / IMS 2026 / ACP, and other evidence-based literature.
· This publication focuses on health for women aged 40+ and evidence-based menopause education.
This article interprets a guideline and provides health education;
it is not diagnosis, treatment advice, or product recommendation.
Hormone therapy is called MHT throughout, commonly HRT in the United States. Make specific treatment decisions with your clinician:
be informed, bring your records, and make decisions together
.
The guideline discussed is ACOG Clinical Practice Guideline No. 13 (2026). This interpretation of publicly available content is for identification, learning, and reference.
Read the source material
The original archive manuscript is restored above. These additional references offer context; their inclusion does not constitute medical validation of every original claim. Clinical and regional terminology review are pending.
A good question starts a conversation.
Explore a related editorial discussion. Reading is open to everyone; posting and replying require a free reader account.


